These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8499583)

  • 1. Pharmacokinetics and pharmacodynamics of valproate analogs in rats. II. Pharmacokinetics of octanoic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid.
    Liu MJ; Pollack GM
    Biopharm Drug Dispos; 1993 May; 14(4):325-39. PubMed ID: 8499583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of valproate analogs in rats. III. Pharmacokinetics of valproic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid in the bile-exteriorized rat.
    Liu MJ; Brouwer KL; Pollack GM
    Drug Metab Dispos; 1992; 20(6):810-5. PubMed ID: 1362931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of valproate analogues in rats. IV. Anticonvulsant action and neurotoxicity of octanoic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid.
    Liu MJ; Pollack GM
    Epilepsia; 1994; 35(1):234-43. PubMed ID: 8112253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of valproate analogues in rats. I. Spiro[4.6]undecane-2-carboxylic acid.
    Liu MJ; Scott KR; Pollack GM
    Epilepsia; 1990; 31(4):465-73. PubMed ID: 2114971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concentration-dependent disposition of glucuronide metabolite of valproate.
    Yu HY; Shen YZ
    J Pharm Pharmacol; 2002 May; 54(5):633-9. PubMed ID: 12005358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: phase II metabolism and pharmacokinetics.
    Tang W; Abbott FS
    Drug Metab Dispos; 1997 Feb; 25(2):219-27. PubMed ID: 9029053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein binding and hepatobiliary distribution of valproic acid and valproate glucuronide in rats.
    Brouwer KL; Hall ES; Pollack GM
    Biochem Pharmacol; 1993 Feb; 45(3):735-42. PubMed ID: 8442771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologic and metabolic influences on enterohepatic recirculation: simulations based upon the disposition of valproic acid in the rat.
    Pollack GM; Brouwer KL
    J Pharmacokinet Biopharm; 1991 Apr; 19(2):189-225. PubMed ID: 2013839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data?
    Ward ES; Pollack GM; Brouwer KL
    Drug Metab Dispos; 2000 Dec; 28(12):1433-9. PubMed ID: 11095580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions.
    Booth CL; Pollack GM; Brouwer KL
    Hepatology; 1996 Apr; 23(4):771-80. PubMed ID: 8666331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, anticonvulsant efficacy, and adverse effects of trans-2-en-valproate after acute and chronic administration in amygdala-kindled rats.
    Hönack D; Rundfeldt C; Löscher W
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Feb; 345(2):187-96. PubMed ID: 1570023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent pharmacokinetics and metabolism of valproic acid in newborn lambs and adult sheep.
    Wong H; Rurak DW; Kumar S; Kwan E; Abbott FS; Riggs KW
    Drug Metab Dispos; 2001 May; 29(5):664-75. PubMed ID: 11302932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic analysis of the disposition of valproate in pregnant rats.
    Kobayashi S; Takai K; Iga T; Hanano M
    Drug Metab Dispos; 1991; 19(5):972-6. PubMed ID: 1686245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of amoxicillin/clavulanic acid on the pharmacokinetics of valproic acid.
    Lee SY; Huh W; Jung JA; Yoo HM; Ko JW; Kim JR
    Drug Des Devel Ther; 2015; 9():4559-63. PubMed ID: 26309401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats.
    Blotnik S; Bergman F; Bialer M
    Drug Metab Dispos; 1996 May; 24(5):560-4. PubMed ID: 8723737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives.
    Levi M; Yagen B; Bialer M
    Pharm Res; 1997 Feb; 14(2):213-7. PubMed ID: 9090712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependent pharmacokinetics of toxic metabolites is not related to increased toxicity following high-dose valproic acid in rats.
    Jung BH; Kim BJ; Lee MS; Lee JH; Oh JH; Lee YJ
    J Appl Toxicol; 2010 Nov; 30(8):775-8. PubMed ID: 21157986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition and protein binding of valproic acid in the developing rat.
    Haberer LJ; Pollack GM
    Drug Metab Dispos; 1994; 22(1):113-9. PubMed ID: 8149869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid.
    Rettenmeier AW; Gordon WP; Prickett KS; Levy RH; Baillie TA
    Drug Metab Dispos; 1986; 14(4):454-64. PubMed ID: 2873993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between glucuronide conjugate levels and hepatotoxicity after oral administration of valproic acid.
    Lee MS; Lee YJ; Kim BJ; Shin KJ; Chung BC; Baek DJ; Jung BH
    Arch Pharm Res; 2009 Jul; 32(7):1029-35. PubMed ID: 19641884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.